Table 2.

Susceptibility to childhood immune thrombocytopenia

Healthy controls (N = 180)Newly diagnosed ITP (N = 180)PP (FDR adjusted)OR (95% CI)
0123401234
Number of copies
 CNR10 (0)12 (6)155 (86)12 (7)1 (1)0 (0)12 (7)152 (84)16 (9)0 (0).781.0
 CNR20 (0)1 (1)168 (93)11 (6)0 (0)0 (0)0 (0)173 (96)7 (4)0 (0).351.0
 CNR30 (0)0 (0)180 (100)0 (0)0 (0)0 (0)0 (0)180 (100)0 (0)0 (0)NDND
Alleles
 FCGR2A*27W146 (81)29 (16)5 (3)0 (0)0 (0)127 (71)49 (27)4 (2)0 (0)0 (0).0330.301.94 (1.17-3.29)*
 FCGR2A*131H38 (21)87 (48)55 (31)0 (0)0 (0)39 (22)95 (53)46 (26)0 (0)0 (0).561.0
 FCGR2B*232T143 (79)31 (17)6 (3)0 (0)0 (0)137 (76)40 (22)3 (2)0 (0)0 (0).341.0
 FCGR2C*ORF143 (79)32 (18)5 (3)0 (0)0 (0)122 (68)56 (31)2 (1)0 (0)0 (0).007.081.84 (1.14-2.98)
 FCGR2C*ncORF173 (96)3 (2)4 (2)0 (0)0 (0)170 (94)3 (2)7 (4)0 (0)0 (0).641.0
 FCGR3A*158V79 (44)78 (43)23 (13)0 (0)0 (0)62 (34)85 (47)33 (18)0 (0)0 (0).141.0
 FCGR3B*NA231 (17)79 (44)68 (38)2 (1)0 (0)20 (11)83 (46)77 (43)0 (0)0 (0).171.0
 FCGR3B*SH173 (96)7 (4)0 (0)0 (0)0 (0)172 (96)8 (4)0 (0)0 (0)0 (0)1.01.0
 FCGR2 promoter 2B.4145 (81)31 (17)4 (2)0 (0)0 (0)134 (74)46 (26)0 (0)0 (0)0 (0).020.201.42 (0.87-2.35)
  • Data are n (% of cohort). Number of copies are given for the respective copy number region (CNR). Frequency P value by Fisher's exact test. Bold values denote statistically significant P values. FCGR3B*NA2 and FCGR3B*SH are also described as FCGR3B*02 and FCGR3B*03 according to recent nomenclature.51

  • CI, confidence interval; FDR, adjustment of P values by false discovery rate; ND, not performed; OR, odds ratio.

  • * OR given for comparison of 27Q/W vs 27Q/W in association with ITP.

  • OR given for presence of 1 or 2 copies vs absence of the variant in association with ITP.